Olaparib AZD-2281 CAS 763113-22-0 Puritas ≥99.0% API Factory
Alta Puritas, Commercial Productio
Olaparib et intermediis Related:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl) methyl) acidum benzoicum CAS 763114-26-7
1-(Cyclopropylcarbonyl) piperazinum hydrochloridum CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonicum Acidum CAS 61260-15-9
| Nomen chemicum | Olaparib |
| Synonyma | AZD-2281;KU0059436;Lynparza;4-(3-(4-(cyclopropanecarbonyl)piperazinum-1-carbonyl) -4-fluorobenzyl) phthalazin-1(2H)-unum;1-(Cyclopropylcarbonyl) -4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin |
| CAS Number | 763113-22-0 |
| CATTUS Number | RF-API103 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C24H23FN4O3 |
| M. Pondus | 434.46 |
| Solubilitas | Solutum in DMSO |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba ad Off-White pulveris |
| Lepidium sativum per 1H NMR | Ad propinquos meos structuram |
| LC-MS | Ad propinquos meos structuram |
| Puritas / Analysis Methodus | ≥99.0% (per LC-MS) |
| Humor (KF) | ≤0.50% |
| una immunditia | ≤0.50% |
| Totalis immunditias | ≤1.0% |
| Metalla gravia (ut Pb) | ≤20ppm |
| Test Standard | Enterprise Standard |
| Consuetudinem | API;PARP Inhibitor |
sarcina: Utrem, aluminium foil, pera, cardboard Drum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
Olaparib (CAS: 763113-22-0), potentissima et selectiva PARP-inhibitor.Mense Decembri 19 2014, FDA approbavit novum anti-cancri medicamentum Olaparib (Lynparza) pro monotherapia aegrotis cancri ovarii provecti, qui saltem 3 circuitus chemotherapii vel aegros mutationum suspectarum BRCA passus est.Eodem tempore FDA probavit quantitatem et classificationem diagnostica kits deprehendendi mutationum in BRCA1 et BRCA2, BRACAnalysis CDx.Olaparib est primus inhibitor medicinae PARP quae ab FDA probata est.Mense Februario die 2 2015, Unionis Europaeae Food et Drug Administration (EMA) Olaparib etiam approbavit ut mercatum in 28 regionibus Unionis Europaeae inter Islandiam, Liechtenstein et Norvegiam iniret.Sed indicia EMA et FDA adprobata paulo diversa sunt;prior est pro casuum mutationis gene BRCA, et etiam pro therapiis conservandis cancri ovarii epithelialis provectae, qui antea platinum-continens chemotherapy medicamenta accepit, et responsionem exhibet et recursum subiciebat.
